{"title":"Pembrolizumab在PD-L1表达以外的晚期NSCLC中的反应预测因子","authors":"B. Khamar","doi":"10.31579/2640-1053/056","DOIUrl":null,"url":null,"abstract":"Pembrolizumab has significantly improved outcome of advanced NSCLC. PD-L1 expression has limited utility as a prognostic and predictive biomarker. To improve this several other biomarkers have been evaluated. Useful amongst them are 1. Tumor specific biomarkers include tumor mutation burden, immune cell infiltration (phenotype, genotype, site, type), 2. Changes in cellular, cytokine in peripheral blood. The article provides review of the current status.","PeriodicalId":93018,"journal":{"name":"Journal of cancer research and cellular therapeutics","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Response Predictors for Pembrolizumab in Advanced NSCLC beyond PD-L1 Expression\",\"authors\":\"B. Khamar\",\"doi\":\"10.31579/2640-1053/056\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Pembrolizumab has significantly improved outcome of advanced NSCLC. PD-L1 expression has limited utility as a prognostic and predictive biomarker. To improve this several other biomarkers have been evaluated. Useful amongst them are 1. Tumor specific biomarkers include tumor mutation burden, immune cell infiltration (phenotype, genotype, site, type), 2. Changes in cellular, cytokine in peripheral blood. The article provides review of the current status.\",\"PeriodicalId\":93018,\"journal\":{\"name\":\"Journal of cancer research and cellular therapeutics\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-11-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of cancer research and cellular therapeutics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.31579/2640-1053/056\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of cancer research and cellular therapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31579/2640-1053/056","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Response Predictors for Pembrolizumab in Advanced NSCLC beyond PD-L1 Expression
Pembrolizumab has significantly improved outcome of advanced NSCLC. PD-L1 expression has limited utility as a prognostic and predictive biomarker. To improve this several other biomarkers have been evaluated. Useful amongst them are 1. Tumor specific biomarkers include tumor mutation burden, immune cell infiltration (phenotype, genotype, site, type), 2. Changes in cellular, cytokine in peripheral blood. The article provides review of the current status.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
